CD19 and B-cell chronic lymphocytic leukemia: For instance, a multicenter study of CD19-targeted CAR-T cell therapy in patients with Richter’s transformation (RT) from CLL demonstrated a median OS of 25.8 months for the entire cohort, with a notably shorter median OS of 12.3 months for patients who had received prior non-CIT CLL treatment.